The gastrointestinal tract contains a diverse and dynamic population of microorganisms called the gut microbiota, which is essential for immune system regulation. Recent studies have highlighted that gut microbiota has a major influence on the effectiveness of cancer immunotherapy, particularly immune checkpoint antagonists. This review explores the mechanisms of specific gut microbiota, such as Bifidobacterium and Lactobacillus, to enhance innate and adaptive immune responses, including activation of dendritic cells, polarization of macrophages, and stimulation of CD8+ T cells. In addition, this review discusses therapeutic strategies aimed at manipulating the gut microbiota to enhance the effects of immunotherapy, including fecal microbiota transplantation (FMT), probiotics, and engineered microbiota. Although these approaches have promising potential, the challenges still remain with the variability of patients and microbiota manipulation. This review emphasizes how crucial it is to combine immunotherapy and the gut microbial community to create more individualized, effective cancer treatments, which will eventually improve patient outcomes and advance the area of cancer treatment.